title: Percutaneous treatment of superior vena cava syndrome using metallic stents.
abstract: The purpose of this study was to evaluate the results of treatment of superior vena cava syndrome (SVCS) in patients with benign and malignant disease using expandable metallic stent. From January 1995 to April 2000, 87 expandable stents were implanted in 82 patients (59 men, 23 women; mean age 57.8 years, age range 39-79 years) for the treatment of SVCS. The SVCS was defined as symptomatic bilateral obstruction of venous drainage from head, neck and upper extremities. In 68 patients SVCS was due to malignant neoplasia, and in 14 cases it was due to benign aetiology. All patients were treated with expandable stent. We implanted 81 Wallstent prostheses and 6 Palmaz stents. Adjuvant thrombolysis was applied in 12 patients who required fibrinolysis. After recanalization, the stent was implanted in all cases in SVC (infra- or supra-azygos vein). All patients were treated with heparin of low molecular weight (HBPM) during 6 months. Patency was analyzed according to clinical symptoms and Doppler US or venograms exploration. Technical success was observed in all cases. Clinical success was reached in 78 of 82 patients (95.1%) (absence of symptoms in 2 or 3 days). Four patients suffered immediate thrombosis which required fibrinolitic treatment with a new prosthesis placement in 1 case. The follow-up for the malignant process was of 7.1 months (range 1-39 months) and in benign cases was 31.2 months (range 11-61 months). Sixty-two (91.1%) patients with malignancy died without SVCS symptomatology. All the patients with benign pathology are alive. Clinical primary patency in malignant cases was 87% with assisted patency of 96.2%. Endovascular therapy using metallic stent and thrombolysis is a successful method to treat SVCS due to benign or malignant aetiology.
authors.affiliation: Department of Interventional Radiology, Lozano Blesa University Hospital, Avda San Juan Bosco 15, 50009 Zaragoza, Spain. mgregori@separ.es
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: de Gregorio Ariza
authors.forename: Pablo
authors.initials: P
authors.lastname: Gamboa
authors.forename: María José
authors.initials: MJ
authors.lastname: Gimeno
authors.forename: Eduardo
authors.initials: E
authors.lastname: Alfonso
authors.forename: Antonio
authors.initials: A
authors.lastname: Mainar
authors.forename: Joaquin
authors.initials: J
authors.lastname: Medrano
authors.forename: Paloma
authors.initials: P
authors.lastname: López-Marin
authors.forename: Ricardo
authors.initials: R
authors.lastname: Tobio
authors.forename: Marcos
authors.initials: M
authors.lastname: Herrera
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D011859:Radiography; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors
chemical_list: D006493:Heparin